{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T19:42:04Z","timestamp":1790624524084,"version":"4.1.0"},"reference-count":70,"publisher":"Harborside Press, LLC","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:p>\n                    <jats:bold>Background:<\/jats:bold>\n                    Some patients with cancer who initially benefit from checkpoint inhibitors (CPIs) achieve lasting remission or cure. Acquired resistance to immunotherapy (ARI) refers to disease progression occurring after an initial period of clinical benefit from immune checkpoint blockade. Despite its clinical relevance, the incidence of ARI across tumor types remains largely unknown. We aimed to estimate the overall incidence of ARI across tumor types and examine its association with tumor response.\n                    <jats:bold>Methods:<\/jats:bold>\n                    ARI rates were estimated using a pooled analysis of digitized progression-free survival (PFS) curves from EMA- and FDA-approved phase III trials of CPIs in solid tumors. Only tumors with an overall response rate (ORR) to CPIs \u226520% were considered. PFS \u22656 months was used as a proxy for response to CPIs, based on the Society for Immunotherapy of Cancer (SITC) definition of ARI. Cancer mortality data from GLOBOCAN 2022 were used to estimate the annual incidence of advanced disease across tumor types.\n                    <jats:bold>Results:<\/jats:bold>\n                    Reconstructed pseudo-individual patient data from 15,199 patients across 11 tumor types and 41 phase III trials were included. The estimated pan-cancer weighted rate of ARI was 73.5% (95% CI, 71.6\u201375.4) at 3 years, ranging from 25.4% in deficient mismatch repair colorectal cancer to 83.1% in squamous esophageal carcinoma; approximately 1,001,815 patients per year may develop ARI globally. RECIST 1.1 complete response (CR), partial response (PR), and stable disease (SD) rates correlated with ARI (CR and PR: \u03c1 = \u20130.63 and \u20130.66;\n                    <jats:italic>P<\/jats:italic>\n                    =.044 and .031, respectively; SD: \u03c1 = +0.68;\n                    <jats:italic>P<\/jats:italic>\n                    =.025), and these associations remained consistent after adjusting for tumor type.\n                    <jats:bold>Conclusions:<\/jats:bold>\n                    A considerable proportion of patients who respond to CPIs develop ARI. The variability in ARI incidence across tumor types is explained by the rates of CR, PR, and SD, indicating that the strength of the antitumor response, rather than tumor histology, informs ARI rates.\n                  <\/jats:p>","DOI":"10.6004\/jnccn.2025.7142","type":"journal-article","created":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T20:31:48Z","timestamp":1778185908000},"page":"244-250","source":"Crossref","is-referenced-by-count":3,"title":["Acquired Resistance to Immune Checkpoint Inhibitors Across Tumor Types: A Reconstructed Individual Patient Data Analysis"],"prefix":"10.6004","volume":"24","author":[{"given":"Yago","family":"Garitaonaindia","sequence":"first","affiliation":[{"name":"National Center for Cancer Immune Therapy (CCIT-DK), Copenhagen University Hospital, Herlev and Gentofte, Herlev, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rikke","family":"Andersen","sequence":"additional","affiliation":[{"name":"National Center for Cancer Immune Therapy (CCIT-DK), Copenhagen University Hospital, Herlev and Gentofte, Herlev, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Presti","sequence":"additional","affiliation":[{"name":"National Center for Cancer Immune Therapy (CCIT-DK), Copenhagen University Hospital, Herlev and Gentofte, Herlev, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Donia","sequence":"additional","affiliation":[{"name":"National Center for Cancer Immune Therapy (CCIT-DK), Copenhagen University Hospital, Herlev and Gentofte, Herlev, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4047","reference":[{"key":"B1","series-title":"Science","first-page":"1350","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas A","year":"2018","unstructured":"Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science 2018;359:1350\u20131355."},{"key":"B2","series-title":"N Engl J Med","first-page":"11","article-title":"Final, 10-year outcomes with nivolumab plus ipilimumab in advanced melanoma","volume":"392","author":"Wolchok JD","year":"2025","unstructured":"Wolchok JD, Chiarion-Sileni V, Rutkowski P,  Final, 10-year outcomes with nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2025;392:11\u201322."},{"key":"B3","series-title":"J Clin Oncol","first-page":"2339","article-title":"Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score \u2265 50","volume":"39","author":"Reck M","year":"2021","unstructured":"Reck M, Rodr\u00edguez-Abreu D, Robinson AG,  Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score \u2265 50. J Clin Oncol 2021;39:2339\u20132349."},{"key":"B4","series-title":"Ann Oncol","first-page":"1026","article-title":"Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial","volume":"35","author":"Tannir NM","year":"2024","unstructured":"Tannir NM, Albig\u00e8s L, McDermott DF,  Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial. Ann Oncol 2024;35:1026\u20131038."},{"key":"B5","series-title":"J Clin Oncol","first-page":"1546","article-title":"Three-year overall survival with nivolumab plus relatlimab in advanced melanoma from RELATIVITY-047","volume":"43","author":"Tawbi HA","year":"2025","unstructured":"Tawbi HA, Hodi FS, Lipson EJ,  Three-year overall survival with nivolumab plus relatlimab in advanced melanoma from RELATIVITY-047. J Clin Oncol 2025;43:1546\u20131552."},{"key":"B6","series-title":"Nat Rev Cancer","first-page":"498","article-title":"Defining clinically useful biomarkers of immune checkpoint inhibitors in solid tumours","volume":"24","author":"Holder AM","year":"2024","unstructured":"Holder AM, Dedeilia A, Sierra-Davidson K,  Defining clinically useful biomarkers of immune checkpoint inhibitors in solid tumours. Nat Rev Cancer 2024;24:498\u2013512."},{"key":"B7","series-title":"Int J Cancer","first-page":"2352","article-title":"How many people in the US are eligible for and respond to checkpoint inhibitors: an empirical analysis","volume":"156","author":"Haslam A","year":"2025","unstructured":"Haslam A, Olivier T, Prasad V. How many people in the US are eligible for and respond to checkpoint inhibitors: an empirical analysis. Int J Cancer 2025;156:2352\u20132359."},{"key":"B8","series-title":"Cancer Cell","first-page":"443","article-title":"Acquired resistance to immune checkpoint inhibitors","volume":"37","author":"Schoenfeld AJ","year":"2020","unstructured":"Schoenfeld AJ, Hellmann MD. Acquired resistance to immune checkpoint inhibitors. Cancer Cell 2020;37:443\u2013455."},{"key":"B9","series-title":"Trends Mol Med","article-title":"Acquired resistance to immunotherapy in solid tumors","author":"Verdys P","year":"2025","unstructured":"Verdys P, Johansen A, Grupta A,  Acquired resistance to immunotherapy in solid tumors. Trends Mol Med 2025;31:1008\u20131020."},{"key":"B10","series-title":"J Immunother Cancer","first-page":"e000398","article-title":"Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce","volume":"8","author":"Kluger HM","year":"2020","unstructured":"Kluger HM, Tawbi HA, Ascierto ML,  Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce. J Immunother Cancer 2020;8:e000398."},{"key":"B11","series-title":"BMC Med Res Methodol","first-page":"147","article-title":"SurvdigitizeR: an algorithm for automated survival curve digitization","volume":"24","author":"Zhang JZ","year":"2024","unstructured":"Zhang JZ, Rios JD, Pechlivanoglou T,  SurvdigitizeR: an algorithm for automated survival curve digitization. BMC Med Res Methodol 2024;24:147."},{"key":"B12","series-title":"BMC Med Res Methodol","first-page":"111","article-title":"IPDfromKM: reconstruct individual patient data from published Kaplan-Meier survival curves","volume":"21","author":"Liu N","year":"2021","unstructured":"Liu N, Zhou Y, Lee JJ. IPDfromKM: reconstruct individual patient data from published Kaplan-Meier survival curves. BMC Med Res Methodol 2021;21:111."},{"key":"B13","series-title":"Ann Oncol","first-page":"734","article-title":"1109P Association of clinical features with long-term survival in patients with melanoma who responded to distinct checkpoint inhibitors","volume":"35(Suppl 2)","author":"Elleb\u00e6ak E","year":"2024","unstructured":"Elleb\u00e6ak E, Khan S, Borsh TH,  1109P Association of clinical features with long-term survival in patients with melanoma who responded to distinct checkpoint inhibitors. Ann Oncol 2024;35(Suppl 2):734\u2013735."},{"key":"B14","series-title":"CA Cancer J Clin","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray F","year":"2024","unstructured":"Bray F, Laversanne M, Sung H,  Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2024;74:229\u2013263."},{"key":"B15","series-title":"Br J Cancer","first-page":"266","article-title":"Deficient mismatch repair system in patients with sporadic advanced colorectal cancer","volume":"100","author":"Koopman M","year":"2009","unstructured":"Koopman M, Kortman GAM, Mekenkamp L,  Deficient mismatch repair system in patients with sporadic advanced colorectal cancer. Br J Cancer 2009;100:266\u2013273."},{"key":"B16","series-title":"Gastroenterology","first-page":"335","article-title":"Global burden of 5 major types of gastrointestinal cancer","volume":"159","author":"Arnold M","year":"2020","unstructured":"Arnold M, Abnet CC, Neale RE,  Global burden of 5 major types of gastrointestinal cancer. Gastroenterology 2020;159:335\u2013349.e15."},{"key":"B17","series-title":"Ann Oncol","first-page":"992","article-title":"Oesophageal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"33","author":"Obermannov\u00e1 R","year":"2022","unstructured":"Obermannov\u00e1 R, Alsina M, Cervantes A,  Oesophageal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol 2022;33:992\u20131004."},{"key":"B18","series-title":"Ann Oncol","first-page":"358","article-title":"Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"34","author":"Hendriks LE","year":"2023","unstructured":"Hendriks LE, Kerr KM, Menis J,  Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol 2023;34:358\u2013376."},{"key":"B19","series-title":"JCO Glob Oncol","first-page":"e2400409","article-title":"Overcoming financial and access barriers in global cancer care with low-dose immunotherapy: a systematic review","volume":"11","author":"Hoyek C","year":"2025","unstructured":"Hoyek C, Zheng-Lin B, Bauernfeind JJ,  Overcoming financial and access barriers in global cancer care with low-dose immunotherapy: a systematic review. JCO Glob Oncol 2025;11:e2400409."},{"key":"B20","series-title":"Curr Oncol Rep","first-page":"25","article-title":"Prognostic biomarkers for melanoma immunotherapy","volume":"22","author":"Twitty CG","year":"2020","unstructured":"Twitty CG, Huppert LA, Daud AI. Prognostic biomarkers for melanoma immunotherapy. Curr Oncol Rep 2020;22:25."},{"key":"B21","series-title":"Hematol Oncol Clin North Am","first-page":"291","article-title":"Prognostic and predictive immunohistochemistry-based biomarkers in cancer and immunotherapy","volume":"33","author":"Rizk EM","year":"2019","unstructured":"Rizk EM, Gartrell RD, Barker LW,  Prognostic and predictive immunohistochemistry-based biomarkers in cancer and immunotherapy. Hematol Oncol Clin North Am 2019;33:291\u2013299."},{"key":"B22","series-title":"Int J Mol Sci","first-page":"7577","article-title":"Prognostic and predictive biomarkers in the era of immunotherapy for lung cancer","volume":"24","author":"Pabst L","year":"2023","unstructured":"Pabst L, Lopes S, Bertrand B,  Prognostic and predictive biomarkers in the era of immunotherapy for lung cancer. Int J Mol Sci 2023;24:7577."},{"key":"B23","series-title":"Annu Rev Immunol","first-page":"329","article-title":"The three Es of cancer immunoediting","volume":"22","author":"Dunn GP","year":"2004","unstructured":"Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol 2004;22:329\u2013360."},{"key":"B24","series-title":"Nat Commun","first-page":"3075","article-title":"Molecular patterns of resistance to immune checkpoint blockade in melanoma","volume":"15","author":"Lauss M","year":"2024","unstructured":"Lauss M, Phung B, Borch TH,  Molecular patterns of resistance to immune checkpoint blockade in melanoma. Nat Commun 2024;15:3075."},{"key":"B25","series-title":"Cancer Drug Resist","first-page":"55","article-title":"Mechanisms of immunotherapy resistance in small cell lung cancer","volume":"7","author":"Nie Y","year":"2024","unstructured":"Nie Y, Schalper KA, Chiang A. Mechanisms of immunotherapy resistance in small cell lung cancer. Cancer Drug Resist 2024;7:55."},{"key":"B26","series-title":"Cancer Immunol Res","first-page":"1254","article-title":"Coexisting alterations of MHC class I antigen presentation and IFN\u03b3 signaling mediate acquired resistance of melanoma to post-PD-1 immunotherapy","volume":"10","author":"Nielsen M","year":"2022","unstructured":"Nielsen M, Presti M, Sztupinszki Z,  Coexisting alterations of MHC class I antigen presentation and IFN\u03b3 signaling mediate acquired resistance of melanoma to post-PD-1 immunotherapy. Cancer Immunol Res 2022;10:1254\u20131262."},{"key":"B27","series-title":"Cancer Cell","first-page":"209","article-title":"Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer","volume":"42","author":"Memon D","year":"2024","unstructured":"Memon D, Schoenfeld AJ, Ye D,  Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer.  Cancer Cell 2024;42:209\u2013224.e9."},{"key":"B28","series-title":"Genome Med","first-page":"14","article-title":"Tumor microenvironment remodeling after neoadjuvant immunotherapy in non-small cell lung cancer revealed by single-cell RNA sequencing","volume":"15","author":"Hu J","year":"2023","unstructured":"Hu J, Zhang L, Xia H,  Tumor microenvironment remodeling after neoadjuvant immunotherapy in non-small cell lung cancer revealed by single-cell RNA sequencing. Genome Med 2023;15:14."},{"key":"B29","series-title":"Cancers (Basel)","first-page":"2616","article-title":"Complete metabolic response in FDG-PET-CT scan before discontinuation of immune checkpoint inhibitors correlates with long progression-free survival","volume":"13","author":"Schank TE","year":"2021","unstructured":"Schank TE, Forschner A, Sachse MM,  Complete metabolic response in FDG-PET-CT scan before discontinuation of immune checkpoint inhibitors correlates with long progression-free survival. Cancers (Basel) 2021;13:2616."},{"key":"B30","series-title":"Cancer Immunol Immunother","first-page":"1719","article-title":"Discontinuation of immune checkpoint inhibitor (ICI) above 18 months of treatment in real-life patients with advanced non-small cell lung cancer (NSCLC): INTEPI, a multicentric retrospective study","volume":"71","author":"Bilger G","year":"2022","unstructured":"Bilger G, Girard N, Doubre H,  Discontinuation of immune checkpoint inhibitor (ICI) above 18 months of treatment in real-life patients with advanced non-small cell lung cancer (NSCLC): INTEPI, a multicentric retrospective study. Cancer Immunol Immunother 2022;71:1719\u20131731."},{"key":"B31","series-title":"Int J Cancer","first-page":"1870","article-title":"Clinical value of routine [18F]2-fluoro-2-deoxy-d-glucose positron emission tomography scans as a decision tool for early immunotherapy discontinuation in advanced melanoma","volume":"150","author":"Ellebaek E","year":"2022","unstructured":"Ellebaek E, Schina A, Andersen R,  Clinical value of routine [18F]2-fluoro-2-deoxy-d-glucose positron emission tomography scans as a decision tool for early immunotherapy discontinuation in advanced melanoma. Int J Cancer 2022;150:1870\u20131878."},{"key":"B32","series-title":"N Engl J Med","first-page":"1696","article-title":"Neoadjuvant nivolumab and ipilimumab in resectable stage III melanoma","volume":"391","author":"Blank CU","year":"2024","unstructured":"Blank CU, Lucas MW, Scolyer RA,  Neoadjuvant nivolumab and ipilimumab in resectable stage III melanoma. N Engl J Med 2024;391: 1696\u20131708."},{"key":"B33","series-title":"Nat Med","first-page":"504","article-title":"Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial","volume":"27","author":"Cascone T","year":"2021","unstructured":"Cascone T, William WN, Weissferdt A,  Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. Nat Med 2021;27:504\u2013514."},{"key":"B34","series-title":"Ann Oncol","first-page":"692","article-title":"Renal cell carcinoma: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"35","author":"Powles T","year":"2024","unstructured":"Powles T, Albiges L, Bex A,  Renal cell carcinoma: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol 2024;35:692\u2013706."},{"key":"B35","series-title":"EClinicalMedicine","first-page":"103482","article-title":"Impact of platinum-based chemotherapy and CTLA-4 inhibition on acquired resistance to first-line anti- PD-1\/PD-L1 agents in non-small cell lung cancer: a systematic review and reconstructed individual patient data analysis","volume":"88","author":"Oresti S","year":"2025","unstructured":"Oresti S, Salomone F, Nuccio A,  Impact of platinum-based chemotherapy and CTLA-4 inhibition on acquired resistance to first-line anti- PD-1\/PD-L1 agents in non-small cell lung cancer: a systematic review and reconstructed individual patient data analysis. EClinicalMedicine 2025;88:103482."},{"key":"B1","series-title":"Science","first-page":"1350","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas A","year":"2018","unstructured":"Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science 2018;359:1350\u20131355."},{"key":"B2","series-title":"N Engl J Med","first-page":"11","article-title":"Final, 10-year outcomes with nivolumab plus ipilimumab in advanced melanoma","volume":"392","author":"Wolchok JD","year":"2025","unstructured":"Wolchok JD, Chiarion-Sileni V, Rutkowski P,  Final, 10-year outcomes with nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2025;392:11\u201322."},{"key":"B3","series-title":"J Clin Oncol","first-page":"2339","article-title":"Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score \u2265 50","volume":"39","author":"Reck M","year":"2021","unstructured":"Reck M, Rodr\u00edguez-Abreu D, Robinson AG,  Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score \u2265 50. J Clin Oncol 2021;39:2339\u20132349."},{"key":"B4","series-title":"Ann Oncol","first-page":"1026","article-title":"Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial","volume":"35","author":"Tannir NM","year":"2024","unstructured":"Tannir NM, Albig\u00e8s L, McDermott DF,  Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial. Ann Oncol 2024;35:1026\u20131038."},{"key":"B5","series-title":"J Clin Oncol","first-page":"1546","article-title":"Three-year overall survival with nivolumab plus relatlimab in advanced melanoma from RELATIVITY-047","volume":"43","author":"Tawbi HA","year":"2025","unstructured":"Tawbi HA, Hodi FS, Lipson EJ,  Three-year overall survival with nivolumab plus relatlimab in advanced melanoma from RELATIVITY-047. J Clin Oncol 2025;43:1546\u20131552."},{"key":"B6","series-title":"Nat Rev Cancer","first-page":"498","article-title":"Defining clinically useful biomarkers of immune checkpoint inhibitors in solid tumours","volume":"24","author":"Holder AM","year":"2024","unstructured":"Holder AM, Dedeilia A, Sierra-Davidson K,  Defining clinically useful biomarkers of immune checkpoint inhibitors in solid tumours. Nat Rev Cancer 2024;24:498\u2013512."},{"key":"B7","series-title":"Int J Cancer","first-page":"2352","article-title":"How many people in the US are eligible for and respond to checkpoint inhibitors: an empirical analysis","volume":"156","author":"Haslam A","year":"2025","unstructured":"Haslam A, Olivier T, Prasad V. How many people in the US are eligible for and respond to checkpoint inhibitors: an empirical analysis. Int J Cancer 2025;156:2352\u20132359."},{"key":"B8","series-title":"Cancer Cell","first-page":"443","article-title":"Acquired resistance to immune checkpoint inhibitors","volume":"37","author":"Schoenfeld AJ","year":"2020","unstructured":"Schoenfeld AJ, Hellmann MD. Acquired resistance to immune checkpoint inhibitors. Cancer Cell 2020;37:443\u2013455."},{"key":"B9","series-title":"Trends Mol Med","article-title":"Acquired resistance to immunotherapy in solid tumors","author":"Verdys P","year":"2025","unstructured":"Verdys P, Johansen A, Grupta A,  Acquired resistance to immunotherapy in solid tumors. Trends Mol Med 2025;31:1008\u20131020."},{"key":"B10","series-title":"J Immunother Cancer","first-page":"e000398","article-title":"Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce","volume":"8","author":"Kluger HM","year":"2020","unstructured":"Kluger HM, Tawbi HA, Ascierto ML,  Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce. J Immunother Cancer 2020;8:e000398."},{"key":"B11","series-title":"BMC Med Res Methodol","first-page":"147","article-title":"SurvdigitizeR: an algorithm for automated survival curve digitization","volume":"24","author":"Zhang JZ","year":"2024","unstructured":"Zhang JZ, Rios JD, Pechlivanoglou T,  SurvdigitizeR: an algorithm for automated survival curve digitization. BMC Med Res Methodol 2024;24:147."},{"key":"B12","series-title":"BMC Med Res Methodol","first-page":"111","article-title":"IPDfromKM: reconstruct individual patient data from published Kaplan-Meier survival curves","volume":"21","author":"Liu N","year":"2021","unstructured":"Liu N, Zhou Y, Lee JJ. IPDfromKM: reconstruct individual patient data from published Kaplan-Meier survival curves. BMC Med Res Methodol 2021;21:111."},{"key":"B13","series-title":"Ann Oncol","first-page":"734","article-title":"1109P Association of clinical features with long-term survival in patients with melanoma who responded to distinct checkpoint inhibitors","volume":"35(Suppl 2)","author":"Elleb\u00e6ak E","year":"2024","unstructured":"Elleb\u00e6ak E, Khan S, Borsh TH,  1109P Association of clinical features with long-term survival in patients with melanoma who responded to distinct checkpoint inhibitors. Ann Oncol 2024;35(Suppl 2):734\u2013735."},{"key":"B14","series-title":"CA Cancer J Clin","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray F","year":"2024","unstructured":"Bray F, Laversanne M, Sung H,  Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2024;74:229\u2013263."},{"key":"B15","series-title":"Br J Cancer","first-page":"266","article-title":"Deficient mismatch repair system in patients with sporadic advanced colorectal cancer","volume":"100","author":"Koopman M","year":"2009","unstructured":"Koopman M, Kortman GAM, Mekenkamp L,  Deficient mismatch repair system in patients with sporadic advanced colorectal cancer. Br J Cancer 2009;100:266\u2013273."},{"key":"B16","series-title":"Gastroenterology","first-page":"335","article-title":"Global burden of 5 major types of gastrointestinal cancer","volume":"159","author":"Arnold M","year":"2020","unstructured":"Arnold M, Abnet CC, Neale RE,  Global burden of 5 major types of gastrointestinal cancer. Gastroenterology 2020;159:335\u2013349.e15."},{"key":"B17","series-title":"Ann Oncol","first-page":"992","article-title":"Oesophageal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"33","author":"Obermannov\u00e1 R","year":"2022","unstructured":"Obermannov\u00e1 R, Alsina M, Cervantes A,  Oesophageal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol 2022;33:992\u20131004."},{"key":"B18","series-title":"Ann Oncol","first-page":"358","article-title":"Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"34","author":"Hendriks LE","year":"2023","unstructured":"Hendriks LE, Kerr KM, Menis J,  Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol 2023;34:358\u2013376."},{"key":"B19","series-title":"JCO Glob Oncol","first-page":"e2400409","article-title":"Overcoming financial and access barriers in global cancer care with low-dose immunotherapy: a systematic review","volume":"11","author":"Hoyek C","year":"2025","unstructured":"Hoyek C, Zheng-Lin B, Bauernfeind JJ,  Overcoming financial and access barriers in global cancer care with low-dose immunotherapy: a systematic review. JCO Glob Oncol 2025;11:e2400409."},{"key":"B20","series-title":"Curr Oncol Rep","first-page":"25","article-title":"Prognostic biomarkers for melanoma immunotherapy","volume":"22","author":"Twitty CG","year":"2020","unstructured":"Twitty CG, Huppert LA, Daud AI. Prognostic biomarkers for melanoma immunotherapy. Curr Oncol Rep 2020;22:25."},{"key":"B21","series-title":"Hematol Oncol Clin North Am","first-page":"291","article-title":"Prognostic and predictive immunohistochemistry-based biomarkers in cancer and immunotherapy","volume":"33","author":"Rizk EM","year":"2019","unstructured":"Rizk EM, Gartrell RD, Barker LW,  Prognostic and predictive immunohistochemistry-based biomarkers in cancer and immunotherapy. Hematol Oncol Clin North Am 2019;33:291\u2013299."},{"key":"B22","series-title":"Int J Mol Sci","first-page":"7577","article-title":"Prognostic and predictive biomarkers in the era of immunotherapy for lung cancer","volume":"24","author":"Pabst L","year":"2023","unstructured":"Pabst L, Lopes S, Bertrand B,  Prognostic and predictive biomarkers in the era of immunotherapy for lung cancer. Int J Mol Sci 2023;24:7577."},{"key":"B23","series-title":"Annu Rev Immunol","first-page":"329","article-title":"The three Es of cancer immunoediting","volume":"22","author":"Dunn GP","year":"2004","unstructured":"Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol 2004;22:329\u2013360."},{"key":"B24","series-title":"Nat Commun","first-page":"3075","article-title":"Molecular patterns of resistance to immune checkpoint blockade in melanoma","volume":"15","author":"Lauss M","year":"2024","unstructured":"Lauss M, Phung B, Borch TH,  Molecular patterns of resistance to immune checkpoint blockade in melanoma. Nat Commun 2024;15:3075."},{"key":"B25","series-title":"Cancer Drug Resist","first-page":"55","article-title":"Mechanisms of immunotherapy resistance in small cell lung cancer","volume":"7","author":"Nie Y","year":"2024","unstructured":"Nie Y, Schalper KA, Chiang A. Mechanisms of immunotherapy resistance in small cell lung cancer. Cancer Drug Resist 2024;7:55."},{"key":"B26","series-title":"Cancer Immunol Res","first-page":"1254","article-title":"Coexisting alterations of MHC class I antigen presentation and IFN\u03b3 signaling mediate acquired resistance of melanoma to post-PD-1 immunotherapy","volume":"10","author":"Nielsen M","year":"2022","unstructured":"Nielsen M, Presti M, Sztupinszki Z,  Coexisting alterations of MHC class I antigen presentation and IFN\u03b3 signaling mediate acquired resistance of melanoma to post-PD-1 immunotherapy. Cancer Immunol Res 2022;10:1254\u20131262."},{"key":"B27","series-title":"Cancer Cell","first-page":"209","article-title":"Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer","volume":"42","author":"Memon D","year":"2024","unstructured":"Memon D, Schoenfeld AJ, Ye D,  Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer.  Cancer Cell 2024;42:209\u2013224.e9."},{"key":"B28","series-title":"Genome Med","first-page":"14","article-title":"Tumor microenvironment remodeling after neoadjuvant immunotherapy in non-small cell lung cancer revealed by single-cell RNA sequencing","volume":"15","author":"Hu J","year":"2023","unstructured":"Hu J, Zhang L, Xia H,  Tumor microenvironment remodeling after neoadjuvant immunotherapy in non-small cell lung cancer revealed by single-cell RNA sequencing. Genome Med 2023;15:14."},{"key":"B29","series-title":"Cancers (Basel)","first-page":"2616","article-title":"Complete metabolic response in FDG-PET-CT scan before discontinuation of immune checkpoint inhibitors correlates with long progression-free survival","volume":"13","author":"Schank TE","year":"2021","unstructured":"Schank TE, Forschner A, Sachse MM,  Complete metabolic response in FDG-PET-CT scan before discontinuation of immune checkpoint inhibitors correlates with long progression-free survival. Cancers (Basel) 2021;13:2616."},{"key":"B30","series-title":"Cancer Immunol Immunother","first-page":"1719","article-title":"Discontinuation of immune checkpoint inhibitor (ICI) above 18 months of treatment in real-life patients with advanced non-small cell lung cancer (NSCLC): INTEPI, a multicentric retrospective study","volume":"71","author":"Bilger G","year":"2022","unstructured":"Bilger G, Girard N, Doubre H,  Discontinuation of immune checkpoint inhibitor (ICI) above 18 months of treatment in real-life patients with advanced non-small cell lung cancer (NSCLC): INTEPI, a multicentric retrospective study. Cancer Immunol Immunother 2022;71:1719\u20131731."},{"key":"B31","series-title":"Int J Cancer","first-page":"1870","article-title":"Clinical value of routine [18F]2-fluoro-2-deoxy-d-glucose positron emission tomography scans as a decision tool for early immunotherapy discontinuation in advanced melanoma","volume":"150","author":"Ellebaek E","year":"2022","unstructured":"Ellebaek E, Schina A, Andersen R,  Clinical value of routine [18F]2-fluoro-2-deoxy-d-glucose positron emission tomography scans as a decision tool for early immunotherapy discontinuation in advanced melanoma. Int J Cancer 2022;150:1870\u20131878."},{"key":"B32","series-title":"N Engl J Med","first-page":"1696","article-title":"Neoadjuvant nivolumab and ipilimumab in resectable stage III melanoma","volume":"391","author":"Blank CU","year":"2024","unstructured":"Blank CU, Lucas MW, Scolyer RA,  Neoadjuvant nivolumab and ipilimumab in resectable stage III melanoma. N Engl J Med 2024;391: 1696\u20131708."},{"key":"B33","series-title":"Nat Med","first-page":"504","article-title":"Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial","volume":"27","author":"Cascone T","year":"2021","unstructured":"Cascone T, William WN, Weissferdt A,  Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. Nat Med 2021;27:504\u2013514."},{"key":"B34","series-title":"Ann Oncol","first-page":"692","article-title":"Renal cell carcinoma: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"35","author":"Powles T","year":"2024","unstructured":"Powles T, Albiges L, Bex A,  Renal cell carcinoma: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol 2024;35:692\u2013706."},{"key":"B35","series-title":"EClinicalMedicine","first-page":"103482","article-title":"Impact of platinum-based chemotherapy and CTLA-4 inhibition on acquired resistance to first-line anti- PD-1\/PD-L1 agents in non-small cell lung cancer: a systematic review and reconstructed individual patient data analysis","volume":"88","author":"Oresti S","year":"2025","unstructured":"Oresti S, Salomone F, Nuccio A,  Impact of platinum-based chemotherapy and CTLA-4 inhibition on acquired resistance to first-line anti- PD-1\/PD-L1 agents in non-small cell lung cancer: a systematic review and reconstructed individual patient data analysis. EClinicalMedicine 2025;88:103482."}],"container-title":["Journal of the National Comprehensive Cancer Network"],"original-title":[],"link":[{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/24\/6\/article-p244.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/24\/6\/article-p244.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/24\/6\/article-p244.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T12:47:58Z","timestamp":1781527678000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/24\/6\/article-p244.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":70,"journal-issue":{"issue":"6"},"URL":"https:\/\/doi.org\/10.6004\/jnccn.2025.7142","relation":{},"ISSN":["1540-1405","1540-1413"],"issn-type":[{"value":"1540-1405","type":"print"},{"value":"1540-1413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]}}}